MET and non-small cell lung carcinoma: In this regard, Guibert and colleagues demonstrated the ability of amplicon-based NGS to identify both genomic alterations commonly associated to EGFR TKI resistance (i.e., MET and ERBB2 amplifications) and novel mutations (i.e., EGFR Q791P) in serial plasma samples from osimertinib treated NSCLC patients, even several months before clinical progression [77].